SyntheMed REPEL-CV Receives Russian Approval
SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
Read more »SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.
Read more »SyntheMed Nominated for Frost & Sullivan Award
The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.
Read more »SyntheMed’s REPEL-CV Approved by Australian Regulators
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.
Read more »State of the Art: Anti-Adhesion Barriers
Many patients are concerned about the external scars that form following surgical procedures, but a much greater risk can come from internal scarring. Adhesions are a type of post-surgical scar tissue that forms between two internal organs or surfaces that are normally separated.
Read more »